消化道肿瘤体外化疗药物敏感性与临床特征的相关性

摘要

目的 探讨消化道肿瘤体外化疗药物敏感性与临床特征的相关性.方法 运用MTT法检测MMC(丝裂霉素)、5-Fu(5-氟脲嘧啶)、DDP(顺铂)化疗药物对30例中晚期消化道肿瘤患者手术切除标本的抑制率,探讨其与患者临床分期的相关性.结果 MMC最大抑制率为85.5%,最小抑制率为6.3%,平均抑制率为42.2%;5-Fu最大抑制率为81.2%,最小抑制率为4.4%,平均抑制率为35.6%;DDP最大抑制率为58.7%,最小抑制率为0,平均抑制率为31.2%.各药物的敏感性与肿瘤分期无相关性(P>0.05).结论 体外肿瘤药敏试验可以判定各化疗药对肿瘤组织的敏感性,可为临床标准化化疗用药及个体化化疗提供依据,对消化道肿瘤的辅助化疗有一定帮助.%Objective To study the correlation between in vitro chemo sensitivity and clinical features of gastrointestinal tumors. Methods Inhibition rates of MMC fmitomycin), 5-Fu (5 - Fluorouracil) and DDP (cisplatin) of surgical resected specimens in 30 patients with advanced gastrointestinal cancer were detected with MTI assay, and the correlation between inhibition rates and clinical stages was explored. Results MMC maximum inhibition rate was 85.5% and minimum inhibition rate was 6.3%, with an average inhibition rate of 42.2%; 5-Fu maximum inhibition rate was 81.2% and minimum inhibition rate was 4.4%, with an average inhibition rate of 35.6%;; DDP maximum inhibition rate was 58.7% and minimum inhibition rate was 0, with an average inhibition rate was 31.2%. Drug susceptibility and tumor stage were not related (P > 0.05). Conclusion The in vitro tumor susceptibility testing can determine the sensitivity of tumor tissue to various chemotherapy drugs and can provide evidence for clinical standardized and individualized chemotherapy, which is useful for adjuvant chemotherapy of gastrointestinal tumors.